Theratechnologies (THTX) announced that it has closed on a $40 million three-year non-dilutive, senior secured syndicated financing with TD Bank, as agent. The new credit facilities include a $20 million accordion feature, which could expand total commitments up to $60 million. Investissement Quebec, the Company’s largest shareholder, has also agreed to provide a $15 million second ranking secured subordinated term loan. Net proceeds from the new loans together with cash on hand will be used to repay all obligations including prepayment penalties under the Company’s existing facility with affiliates of Marathon Asset Management, pursuant to the credit agreement entered into with Marathon in July 2022, and to fund business development activities.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THTX:
- Theratechnologies Resubmits Tesamorelin Application to FDA
- Theratechnologies submits updated tesamorelin F8 forumlation for FDA review
- Theratechnologies unveils study design of PROMISE-US trial of ibalizumab
- Theratechnologies downgraded to Hold from Buy at JonesResearch
- Delta reports mixed Q3, Domino’s reports earnings beat: Morning Buzz